Immunoglobulin G amplifies the production of regulatory rheumatoid factor in vitro through idiotype-anti-idiotype interactions.

Immunoglobulin G amplifies the production of regulatory rheumatoid factor in vitro through idiotype-anti-idiotype interactions. J Immunoassay Immunochem. 2020 Jan 12;:1-12 Authors: Beduleva L, Stolyarova E, Sidorov A, Khramova T, Terentiev A, Menshikov I, Abisheva N, Snigiryev A, Fomina K Abstract Immunoglobulin G can inhibit antibody response. The mechanism of immunosuppression by immunoglobulins remains unknown. Recently, we found a new factor of immunoregulation referred to as regulatory rheumatoid factor (regRF). RegRF prevents autoimmunity and reduces experimental autoimmune reactions. RegRF comprises a population of anti-idiotypic antibodies that have a unique paratope specific to the antigen-binding sites of the antibodies, and a shared paratope specific to neoepitopes of IgG Fc fragments. Given the specificity of regRF, we can anticipate that IgG would be able to induce regRF production, and consequently that the immunosuppressive effect of IgG may be mediated by regRF. We found that IgG induces regRF production in a culture of B lymphocytes obtained from the red bone marrow of intact rats. IgG does not expose neoepitopes recognized by the shared paratope of regRF, and does not acquire them in culture. Therefore, the stimulation of regRF production induced by IgG is not a result of the interaction between the shared paratope of regRF and the neoepitopes of IgG. Fc fragments of IgG are unable to stimulate regRF production. Fab fragments inhibit spo...
Source: Journal of Immunoassay and Immunochemistry - Category: Biochemistry Tags: J Immunoassay Immunochem Source Type: research

Related Links:

CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
FDA has granted Emergency Use Authorization (EUA) to Battelle's CCDS Critical Care Decontamination System for processing up to 80,000 respirator masks per system each day. CCDS employs concentrated, vapor-phase hydrogen peroxide (VPHP) for decontamination. The system has been validated to decontaminate masks of SARS-CoV-2, the company reported. The masks are placed on shelves inside a container, and a portable, external VPHP system is hooked up to the outside of container. The system was first envisioned by Battelle as part of a study commissioned by FDA in 2015. That study involved determining the feasibility of N95 respi...
Source: MDDI - Category: Medical Devices Authors: Tags: Sterilization Source Type: news
Source: BMJ Comments - Category: General Medicine Source Type: forums
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Jorge A Alfaro-Murillo, Marí L Ávila-Agüero, Meagan C Fitzpatrick, Caroline J Crystal, Luiza-Helena Falleiros-Arlant, Alison P Galvani
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Stephen W Russell, Brian T Garibaldi, Andrew Elder, Abraham Verghese
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s):
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Fathiah Zakham, Olli Vapalahti, Hilal A Lashual
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Renato D Lopes, Claudio Gimpelewicz, John J V McMurray
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Genichi Sugihara, Nori Takei
Source: The Lancet - Category: General Medicine Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Gorka Orive, Unax Lertxundi
Source: The Lancet - Category: General Medicine Source Type: research
More News: Biochemistry | Men | Rheumatology